Greg Plowman, M.D., Ph.D., has been appointed to lead Lilly’s oncology research efforts as the vice president of oncology research, and senior vice president of ImClone Systems research. Dr. Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone, and will be based at ImClone’s Alexandria Center for Life Science in New York City. He reports to Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories (LRL), and Bernhard Ehmer, M.D., president of ImClone.

“Oncology represents a major area of unmet medical need and rapidly advancing science is driving us to discover new treatments with better efficacy to prolong the survival of the patients we serve,” said Dr. Lundberg. “The introduction of a new oncology research leader across Lilly and ImClone will ensure the pursuit of the right mechanisms, therapeutic agents and tailoring strategies across our oncology business. Greg’s position is unique and his experience makes him an ideal choice for this new position.”

Most recently, Dr. Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He directed research efforts in anti-angiogenesis, biomedical imaging, and tumor biology, and was responsible for building a pipeline of new agents for treatment of cancer and ocular disease. He has 25 years of experience in cancer research including leadership roles at Oncogen, Sugen, Exelixis and Genentech (now Bristol-Myers Squibb, Pharmacia and Roche).